{"entity":{"id":"nct06558214","kind":"trial","name":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","aka":["OPTIMUS PRIME"],"tldr":"A phase 2 trial of Laser interstitial thermal therapy systems in Glioma & glioblastoma, run by University of Florida, now recruiting.","summary":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial is a phase 2 interventional study registered as NCT06558214 by University of Florida, with 20 participants planned, started 2024-12-10 and due to reach its primary completion in 2029-10. Interventions recorded: Pembrolizumab, Optune GIO®, NeuroBlate®. Conditions recorded: Recurrent Glioblastoma.\n\nLinked to the technology Laser interstitial thermal therapy systems because the registry names it (\"neuroblate\") among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06558214","url":"https://clinicaltrials.gov/study/NCT06558214"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["litt-systems"],"targets":[],"drugs":["pembrolizumab","optune"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06558214","phase":"2","setting":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","sponsor":"University of Florida","participation":[{"nct":"NCT06558214","source":"https://clinicaltrials.gov/study/NCT06558214","fetchedAt":"2026-10-07T16:54:48.431Z","studySha256":"bf1e9e06632c3dda9a5be8ece178284649328f680737c76e7b02cc3205474eee","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"University of Florida","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"90 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":20,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2024-12-10","startedType":"actual","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06558214/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"litt-systems","kind":"technology","name":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","route":"/technologies/litt-systems/"}],"drug":[{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}